An Experimental And Clinical Study Of Dendritic Cell-based Immunotherapy For Patients With Primary Hepatocellular Carcinoma

Primary liver cancer (PLC) is one of the most common cancers in our country and the incidence of PLC is steadily increasing. Although treatment options and therapy effectc has been improved significantly in the near twenty years, intrahepatic recurrence and extrahepatic recurrence occur frequently, limiting patients survival. It is, thus, paramount to develop novel strategies for cure of this disease and for preventment of the recurrence and matastasis of PLC. Dendritic cell(DC) is one of the most powerful antigen present cells, DC has special presenting antigen and stimulating functions and is the core of immune reaction. DC play a important role in anti-tumor immunity. Using DC to establish a special and persistent immune response not only is the foundation of dendritic cell-based tumor vaccines, but also is a new and prospective tumor immunotherapy, it may play a important role in tumor treatment and preventing tumor occurrence ,recurrence and metastasis.This article was composed of four parts. It studied the relationship of DC and the occrrence and development of PLC, the DC amplification in vitro and the immunology function induced from the peripheral blood of PLC patients, studied the preparation ,anti-tumor effect and mechanism of DC tumor vaccines loaded with hepatocarcinoma cells antigen, studied the safe and clinical effects of DC tumor vaccines. We gained many significant results and summarized as follow.The first part, we investigated the number and clinical significance of tumor infiltrating dendritic cell (TIDC) of hepatocarcinoma tissues. The infiltrating of TIDC, memorial T lymphocyte(CD45RO~+T lymphocyte), CD4~+ T lymphocyte, CD8~+T lymphocyte and the proliferating cell nuclear antigen...